Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity

J Bone Miner Res. 2015 May;30(5):753-64. doi: 10.1002/jbmr.2496.

Combined therapy remains a potentially valuable approach to therapy. Because studies of antifracture efficacy comparing combined with single therapy are unlikely to be performed in humans, efforts should be directed toward improving methods of quantifying the net effects of combined therapy on bone’s material composition, microarchitecture, and strength.

Autor: E, Martin TJ.
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada